---
type: "Nootropic"
title: "PQQ (Pyrrolo Quinoline Quinone)"
description: "PQQ is a redox compound. Mitochondrial biogenesis and neuroprotection findings are mostly cellular or animal data; new brain mitochondria or BDNF-mediated cognitive benefit in humans have not been established."
resource: "https://nootropikler.com/nootropics/pqq"
tags: ["Mitochondria", "Cognition research"]
timestamp: 2026-11-11T00:00:00Z
category: "neurotrophic"
source: "Natural"
latin: "Pyrroloquinoline quinone"
language: "en"
---

# PQQ (Pyrrolo Quinoline Quinone)

*Pyrroloquinoline quinone*

PQQ is a redox compound. Mitochondrial biogenesis and neuroprotection findings are mostly cellular or animal data; new brain mitochondria or BDNF-mediated cognitive benefit in humans have not been established.

## Quick profile

| Property | Value |
| --- | --- |
| Onset of Effect | No established timeframe |
| Dose used in research | No established dose for cognitive use |
| Safety | See detailed safety warnings |

> 2026-11-11 correction: Mouse liver, an open study and a controlled human trial were distinguished. The hydrogen-mineral/PQQ mixture’s BDNF result was bounded by its between-group test. EFSA’s opinion retained its product/population conditions; general half-life and unsupported human BDNF/mitochondria claims were removed.

## What is PQQ?

PQQ is a redox compound. Mitochondrial biogenesis and neuroprotection findings are mostly cellular or animal data; new brain mitochondria or BDNF-mediated cognitive benefit in humans have not been established.

## Mechanism of Effect

Stites et al. (2006) studied dietary PQQ and liver mitochondrial amount and function, particularly in developing mice; some measurements changed with a PQQ-deprived diet.

Mouse liver and a special-diet model do not demonstrate increased mitochondria or BDNF in the human brain. This experiment does not establish human PQQ deficiency, an essential nutrient requirement or cognitive benefit.

## Clinical Trials

Nakano et al. (2012) studied self-reported stress, fatigue and sleep in an open-label trial of 17 adults taking 20 mg/day PQQ for 8 weeks. There was no placebo group; it did not demonstrate cognitive efficacy or CRP/LDL reductions.

There was no placebo group; self-reported change from baseline is not causal efficacy. This open study does not establish general cognitive benefit, reduced CRP/LDL or combination safety.

Tamakoshi et al. (2023) reported improvement on selected memory measures in a 12-week trial of PQQ disodium salt, 20 mg/day, versus placebo in adults aged 20–65; age-subgroup outcomes and timing differed.

The accessed abstract does not provide the sample size; none was added. Multiple tasks and age subgroups do not establish general cognitive benefit at every age or a personal dose. Authors include Mitsubishi Gas Chemical employees.

In a 2024 trial, 34 older adults with mild cognitive impairment received hydrogen-producing minerals/PQQ mixture or placebo for 6 weeks. Serum BDNF rose within the active group from baseline (p=0.01), but the treatment×time interaction was not significant (p=0.14).

This is not a trial of pure PQQ or chemically “reduced PQQ”; it uses a two-component product. Serum BDNF is not brain BDNF. A secondary orientation finding and multiple measurements do not establish general cognitive efficacy or long-term safety.

## Dose information and research limits

> **Dose information and research limits:** This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

## Safety and Side Effects

The 10–20 mg/day PQQ used in human studies is not an established safe dose for everyone. High-dose animal toxicity findings do not define a safe human threshold. An unreported interaction does not establish safe combined use. Pregnancy and breastfeeding safety data are insufficient; people taking medicines should discuss combined use with a health professional.

EFSA (2017) assessed PQQ disodium salt named BioPQQ as safe under specified manufacturing/product conditions and proposed use up to 20 mg/day in healthy adults excluding pregnant and breastfeeding women.

This product-safety opinion is not cognitive-efficacy evidence or a personal dose recommendation for everyone. It notes that comprehensive renal assessment was absent from human studies. Presence in food does not establish supplement need, pregnancy safety or safe drug combinations.


## Frequently Asked Questions

### What does PQQ do?

PQQ is a redox compound. Mitochondrial biogenesis and neuroprotection findings are mostly cellular or animal data; new brain mitochondria or BDNF-mediated cognitive benefit in humans have not been established.

### Does PQQ increase mitochondria in the human brain?

Mouse liver and a special-diet model do not demonstrate increased mitochondria or BDNF in the human brain. This experiment does not establish human PQQ deficiency, an essential nutrient requirement or cognitive benefit.

### How many mg of PQQ should be taken per day?

Human studies have used 10–20 mg/day PQQ; this is not a personal dosing recommendation. Supplemental PQQ disodium salt is water-soluble; a requirement for fatty meals is unsupported.

### Does the EFSA assessment establish a safe dose for everyone?

This product-safety opinion is not cognitive-efficacy evidence or a personal dose recommendation for everyone. It notes that comprehensive renal assessment was absent from human studies. Presence in food does not establish supplement need, pregnancy safety or safe drug combinations.

## Sources

- Stites T, et al. (2006). Pyrroloquinoline quinone modulates mitochondrial quantity and function in mice. *Journal of Nutrition*, 136(2), 390–396. [PubMed · PMID 16424117](https://pubmed.ncbi.nlm.nih.gov/16424117/)
- Rucker R, et al. (2009). Potential physiological importance of pyrroloquinoline quinone. *Alternative Medicine Review*, 14(3), 268–277. [PubMed · PMID 19803551](https://pubmed.ncbi.nlm.nih.gov/19803551/)
- Misra HS, et al. (2012). Pyrroloquinoline-quinone and its versatile roles in biological processes. *Journal of Biosciences*, 37(2), 313–325. [PubMed · PMID 22581337](https://pubmed.ncbi.nlm.nih.gov/22581337/)
- Nakano M, Yamamoto T, Okamura H, Tsuda A, Kowatari Y. (2012). Effects of Oral Supplementation with Pyrroloquinoline Quinone on Stress, Fatigue, and Sleep. *Functional Foods in Health and Disease*, 2(8), 307–324. https://doi.org/10.31989/ffhd.v2i8.81 [Publisher record · DOI · Functional Food Center](https://doi.org/10.31989/ffhd.v2i8.81)
- Tamakoshi M, et al. (2023). Pyrroloquinoline quinone disodium salt improves brain function in both younger and older adults. *Food & function*, 14(5), 2496-2501. https://doi.org/10.1039/d2fo01515c [PubMed · PMID 36807425](https://pubmed.ncbi.nlm.nih.gov/36807425/)
- Baltic S, et al. (2024). The impact of six-week dihydrogen-pyrroloquinoline quinone supplementation on mitochondrial biomarkers, brain metabolism, and cognition in elderly individuals with mild cognitive impairment: a randomized controlled trial. *The journal of nutrition, health & aging*, 28(8), 100287. https://doi.org/10.1016/j.jnha.2024.100287 [PubMed · PMID 38908296](https://pubmed.ncbi.nlm.nih.gov/38908296/)
- EFSA NDA Panel. (2017). Safety of pyrroloquinoline quinone disodium salt as a novel food pursuant to Regulation (EC) No 258/97. https://www.efsa.europa.eu/en/efsajournal/pub/5058 [European Food Safety Authority](https://www.efsa.europa.eu/en/efsajournal/pub/5058)

## Related nootropics

- [Coenzyme Q10](/okf/nootropics/coenzyme-q10.md)
- [NMN](/okf/nootropics/nmn.md)
- [Lion's Mane](/okf/nootropics/lions-mane.md)
